Storia in 2 fonti

Israeli-founded AI biotech Immunai launches drug-discovery collaboration | The Jerusalem Post

The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases.

Raccontata da

ynetnews.com

jpost.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

jpost.comStai leggendo6 g fa

Israeli-founded AI biotech Immunai launches drug-discovery collaboration | The Jerusalem Post

The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases.

originale

ynetnews.com6 g fa

Immunai signs $15M AI drug discovery deal with Boehringer Ingelheim

Multi-project collaboration, running through 2027, will use Immunai’s single-cell AI platform to identify T-cell dysfunction patterns in cancer and autoimmune diseases and advance new drug discovery programs

Leggi questa versione → originale

Timeline cronologica

giovedì 25 giugno 2026·ynetnews.com
Immunai signs $15M AI drug discovery deal with Boehringer Ingelheim
Multi-project collaboration, running through 2027, will use Immunai’s single-cell AI platform to identify T-cell dysfunction patterns in cancer and autoimmune diseases and advance…
giovedì 25 giugno 2026·jpost.com
Israeli-founded AI biotech Immunai launches drug-discovery collaboration | The Jerusalem Post
The collaboration will use Immunai’s single-cell AI platform to identify T-cell targets in cancer and autoimmune diseases.